Analyses of CD38 antibody mechanisms, primarily from preclinical myeloma models suggest that target cell depletion involves Fc-dependent immune effector processes, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent phagocytosis (ADCP) [27] Additional mechanisms may include interference with CD38’s ectoenzymatic activity, apoptosis induction, or triggering CD38-dependent activation, potentially affecting immune cells like NK cells, where overactivation may cause exhaustion or cell death. Here, CD38 is linked to plasma cell myeloma.